Cargando…

Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy

BACKGROUND: Cardiovascular diseases are the leading cause of death in the USA. Statin therapy reduces cardiovascular events significantly. Cognitive impairment has been reported with statin therapy but there is a lack of consensus. We analyzed the cognitive functions of adult patients who were on mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Satyajeet, Hyman, Daniel, Ayyala, Srinivas, Bakhshi, Aditya, Kim, Sang Hoon, Anoruo, Nancy, Weinstock, Joshua, Balogun, Ayobamidele, D’Souza, Michelle, Filatova, Nika, Penabad, Jesus, Shah, Pratik, Perez, Christopher, Mehta, Anita, Hunter, Krystal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188372/
https://www.ncbi.nlm.nih.gov/pubmed/32362974
http://dx.doi.org/10.14740/jocmr4144
_version_ 1783527300321509376
author Roy, Satyajeet
Hyman, Daniel
Ayyala, Srinivas
Bakhshi, Aditya
Kim, Sang Hoon
Anoruo, Nancy
Weinstock, Joshua
Balogun, Ayobamidele
D’Souza, Michelle
Filatova, Nika
Penabad, Jesus
Shah, Pratik
Perez, Christopher
Mehta, Anita
Hunter, Krystal
author_facet Roy, Satyajeet
Hyman, Daniel
Ayyala, Srinivas
Bakhshi, Aditya
Kim, Sang Hoon
Anoruo, Nancy
Weinstock, Joshua
Balogun, Ayobamidele
D’Souza, Michelle
Filatova, Nika
Penabad, Jesus
Shah, Pratik
Perez, Christopher
Mehta, Anita
Hunter, Krystal
author_sort Roy, Satyajeet
collection PubMed
description BACKGROUND: Cardiovascular diseases are the leading cause of death in the USA. Statin therapy reduces cardiovascular events significantly. Cognitive impairment has been reported with statin therapy but there is a lack of consensus. We analyzed the cognitive functions of adult patients who were on moderate-intensity statin therapy (MIST) or high-intensity statin therapy (HIST). METHODS: A total of 213 patients underwent cognitive assessment testing. Cognitive function scores were correlated with the durations of statin therapy, age, and level of education by using Pearson correlation. Independent t-test was used to compare the mean cognitive function score to the gender, race, type of statin therapy, and comorbid conditions. RESULTS: Mean age of all the patients was 55.4 years. Majority of the patients (66.2%) were on MIST while the rest (33.8%) were on HIST. Cognitive impairment was observed in 17.8% of the studied patients. A total of 41.7% of the patients in the HIST group and 5.7% in the MIST group had cognitive impairment (P < 0.001). There was no correlation between cognitive function score and age (r = -0.106), weakly positive correlation between the level of education and cognitive function score (r = 0.252), and weakly negative correlation between the duration of statin therapy and cognitive function score (r = -0.283). In the group of patients on HIST with cognitive impairment, the proportion of patients on atorvastatin 40 - 80 mg was significantly higher than the proportion of patients on rosuvastatin 20 - 40 mg (66.7% vs. 33.3%; P < 0.05). In the group of patients on MIST with cognitive impairment, atorvastatin 10 - 20 mg was the most commonly used statin therapy (50%), followed by rosuvastatin 10 mg (25%), simvastatin 20 - 40 mg (12.5%) and pravastatin 40 - 80 mg (12.5%). CONCLUSIONS: We found a significantly higher association of cognitive impairment in patients who were on MIST or HIST compared to the general population. We found no correlation between cognitive function score and age, weakly positive correlation between the level of education and cognitive function score, and weakly negative correlation between the duration of statin therapy and cognitive function score. HIST was associated with a higher frequency of cognitive impairment compared to the MIST.
format Online
Article
Text
id pubmed-7188372
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-71883722020-05-01 Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy Roy, Satyajeet Hyman, Daniel Ayyala, Srinivas Bakhshi, Aditya Kim, Sang Hoon Anoruo, Nancy Weinstock, Joshua Balogun, Ayobamidele D’Souza, Michelle Filatova, Nika Penabad, Jesus Shah, Pratik Perez, Christopher Mehta, Anita Hunter, Krystal J Clin Med Res Original Article BACKGROUND: Cardiovascular diseases are the leading cause of death in the USA. Statin therapy reduces cardiovascular events significantly. Cognitive impairment has been reported with statin therapy but there is a lack of consensus. We analyzed the cognitive functions of adult patients who were on moderate-intensity statin therapy (MIST) or high-intensity statin therapy (HIST). METHODS: A total of 213 patients underwent cognitive assessment testing. Cognitive function scores were correlated with the durations of statin therapy, age, and level of education by using Pearson correlation. Independent t-test was used to compare the mean cognitive function score to the gender, race, type of statin therapy, and comorbid conditions. RESULTS: Mean age of all the patients was 55.4 years. Majority of the patients (66.2%) were on MIST while the rest (33.8%) were on HIST. Cognitive impairment was observed in 17.8% of the studied patients. A total of 41.7% of the patients in the HIST group and 5.7% in the MIST group had cognitive impairment (P < 0.001). There was no correlation between cognitive function score and age (r = -0.106), weakly positive correlation between the level of education and cognitive function score (r = 0.252), and weakly negative correlation between the duration of statin therapy and cognitive function score (r = -0.283). In the group of patients on HIST with cognitive impairment, the proportion of patients on atorvastatin 40 - 80 mg was significantly higher than the proportion of patients on rosuvastatin 20 - 40 mg (66.7% vs. 33.3%; P < 0.05). In the group of patients on MIST with cognitive impairment, atorvastatin 10 - 20 mg was the most commonly used statin therapy (50%), followed by rosuvastatin 10 mg (25%), simvastatin 20 - 40 mg (12.5%) and pravastatin 40 - 80 mg (12.5%). CONCLUSIONS: We found a significantly higher association of cognitive impairment in patients who were on MIST or HIST compared to the general population. We found no correlation between cognitive function score and age, weakly positive correlation between the level of education and cognitive function score, and weakly negative correlation between the duration of statin therapy and cognitive function score. HIST was associated with a higher frequency of cognitive impairment compared to the MIST. Elmer Press 2020-04 2020-03-30 /pmc/articles/PMC7188372/ /pubmed/32362974 http://dx.doi.org/10.14740/jocmr4144 Text en Copyright 2020, Roy et al. http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Roy, Satyajeet
Hyman, Daniel
Ayyala, Srinivas
Bakhshi, Aditya
Kim, Sang Hoon
Anoruo, Nancy
Weinstock, Joshua
Balogun, Ayobamidele
D’Souza, Michelle
Filatova, Nika
Penabad, Jesus
Shah, Pratik
Perez, Christopher
Mehta, Anita
Hunter, Krystal
Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy
title Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy
title_full Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy
title_fullStr Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy
title_full_unstemmed Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy
title_short Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy
title_sort cognitive function assessment in patients on moderate- or high-intensity statin therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188372/
https://www.ncbi.nlm.nih.gov/pubmed/32362974
http://dx.doi.org/10.14740/jocmr4144
work_keys_str_mv AT roysatyajeet cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT hymandaniel cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT ayyalasrinivas cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT bakhshiaditya cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT kimsanghoon cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT anoruonancy cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT weinstockjoshua cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT balogunayobamidele cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT dsouzamichelle cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT filatovanika cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT penabadjesus cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT shahpratik cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT perezchristopher cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT mehtaanita cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy
AT hunterkrystal cognitivefunctionassessmentinpatientsonmoderateorhighintensitystatintherapy